Global Expression Vectors Market Size (2024 - 2029)

The expression vectors market is anticipated to experience growth due to increased research and development activities in the pharmaceutical sector, advancements in proteomics, and the rising demand for biologics to address lifestyle diseases, infectious diseases, and genetic disorders. The market's expansion is supported by the need for effective therapeutic and preventive strategies, particularly in the context of the COVID-19 pandemic. Despite these growth drivers, the high cost of protein expression systems may pose a challenge to the market's expansion over the forecast period.

Market Size of Global Expression Vectors Industry

Expression Vectors Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 5.60 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Expression Vectors Market Major Players

*Disclaimer: Major Players sorted in no particular order

Expression Vectors Market Analysis

The expression vectors market is expected to register a CAGR of 5.6% over the forecast period, 2022-2027.

The market has a slightly positive impact due to the pandemic. The development of therapeutic and preventive strategies requires an accurate understanding of the role that proteins play in the SARS-CoV-2 infection process and progression of COVID-19. The vast field of proteomics is well equipped with the technologies needed to help in facing this challenge. In an article published in the Journal of Proteins and Proteomics in October 2020, researchers have highlighted that the developments in proteome technologies will not only accelerate progress in addressing the coronavirus pandemics but could also prove invaluable in tackling the current COVID-19 crisis. According to a report published by Journal of the American College of Cardiology: Basic to Translational Science, on Plasma Proteomics of COVID-19-Associated Cardiovascular Complications, on May 2022, key biological pathways linked to cardiac injury and stress in COVID-19 are identified by plasma proteomics. The von Willebrand factor (VWF)-cleaving protease ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13), whose loss-of-function results in microvascular thrombosis, exhibits the most significant inverse correlation with myocardial damage among the 4,996 analytes examined in COVID-19. The market is expected to gain traction due to the significant increase in the COVID 19 cases globally.

The propelling factors for the growth of the expression vector market include the rise in the R&D activity in the pharmaceutical sector, opportunities in the field of proteomics, and advancements in the biologics market set to boost the market growth and the increasing incidences of lifestyle diseases, infectious diseases and genetic disorders. According to the World Health Organization (WHO) 2021, non-communicable diseases (NCDs) are causative of 41 million deaths yearly, equivalent to 71% of the total death rate. More than 15 million people die each year from non-communicable diseases between 30 and 69 years. About 85% of these "premature" deaths occur in low- and middle-income countries. Also, 77% of all non-communicable disease casualties are in low- and middle-income countries. Cardiovascular diseases account for most non-communicable disease deaths, or 17.9 million fatalities annually, followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). These growing cases of non-communicable diseases are expected to further increase the demand for biologics in treating chronic diseases. Biologics have played a crucial role in the treatment process of many health issues. The growing demand for biologicals increases the prospects of its manufacturing using the expression vector systems, thus, boosting the market growth.

Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However high cost of protein expression systems is expected to hinder the market growth over the forecast period.

Expression Vectors Industry Segmentation

As per the scope of the report, expression vector, also known as an expression construct, are plasmid or virus that is specially designed for expressing genes in a cell. It is a vector widely used for protein production. The expression vectors market is segmented by Host Type (Bacterial Expression Vectors, Mammalian Expression Vectors, Insect Expression Vectors, Yeast Expression Vectors and Other Expression Vectors), Application (Therapeutic Applications, Research Applications and Industrial Applications), End-User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs), and Academic Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Host Type
Bacterial Expression Vectors
Mammalian Expression Vectors
Insect Expression Vectors
Yeast Expression Vectors
Other Expression Vectors
By Application
Therapeutic Applications
Research Applications
Industrial Applications
By End-User
Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs)
Academic Research Institutes
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Expression Vectors Market Size Summary

The expression vectors market is poised for growth, driven by advancements in proteomics and the increasing demand for biologics to address lifestyle diseases, infectious diseases, and genetic disorders. The market's expansion is supported by the rising research and development activities in the pharmaceutical sector and the significant role of expression vectors in the production of recombinant proteins. The COVID-19 pandemic has further highlighted the importance of proteome technologies, which have been instrumental in understanding the virus's impact and developing therapeutic strategies. Despite the high costs associated with protein expression systems, the market is expected to benefit from the growing need for biologics in treating chronic diseases, thereby boosting the adoption of expression vector systems.

North America emerges as the dominant region in the expression vectors market, attributed to its robust healthcare infrastructure and active research and development initiatives. The United States, in particular, is witnessing increased investment in synthetic biology and protein technologies, fueling the market's growth. The competitive landscape is characterized by the presence of several global and regional players, including Thermo Fisher Scientific, Promega Corporation, and Merck KGaA, who are expanding their capabilities through strategic mergers and acquisitions. These developments, along with the rising acceptance of gene and monoclonal antibody-based therapies, are expected to drive the market's growth trajectory over the forecast period.

Explore More

Global Expression Vectors Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increase in Demand of Protein-Based Biologics

      2. 1.2.2 High Prevalence Rate of Lifestyle Diseases, Infectious Diseases and Genetic Disorders

      3. 1.2.3 Funding for Protein Research

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Protein Therapy

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Host Type

      1. 2.1.1 Bacterial Expression Vectors

      2. 2.1.2 Mammalian Expression Vectors

      3. 2.1.3 Insect Expression Vectors

      4. 2.1.4 Yeast Expression Vectors

      5. 2.1.5 Other Expression Vectors

    2. 2.2 By Application

      1. 2.2.1 Therapeutic Applications

      2. 2.2.2 Research Applications

      3. 2.2.3 Industrial Applications

    3. 2.3 By End-User

      1. 2.3.1 Pharmaceutical and Biotechnology Companies

      2. 2.3.2 Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs)

      3. 2.3.3 Academic Research Institutes

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Expression Vectors Market Size FAQs

The Global Expression Vectors Market is projected to register a CAGR of 5.60% during the forecast period (2024-2029)

Thermo Fisher Scientific, Inc., Promega Corporation, Merck KGaA, Agilent Technologies and Bio-Rad Laboratories are the major companies operating in the Global Expression Vectors Market.

Expression Vectors Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)